Technology
Histotripsy 2.0 System for Liver Cancer Treatment
Donated by the Li Ka Shing Foundation, the revolutionary Histotripsy 2.0 system came into service with its first case in May 2025. The non-invasive Histotripsy represents a low-risk and highly effective breakthrough in liver cancer treatment, approved by the U.S. Food and Drug Administration and supported by evidence-based research for clinical use in treating primary or metastatic liver cancer.
The Histotripsy 2.0 system utilises high-intensity focused ultrasound to precisely target liver tumours. It then creates microbubbles within the tumours that rapidly expand and collapse, generating shockwaves to disrupt and liquefy the tumours. The entire procedure is guided by advanced real-time ultrasound imaging, ensuring precise targeting of tumours with minimal impact on the surrounding tissues and significant reduction in treatment side effects. It is a viable option for patients deemed unsuitable for surgical intervention, and those for whom other liver cancer treatments have been ineffective.
As a non-invasive procedure, Histotripsy involves no radiation or thermal energy, thereby resulting in minimal discomfort and no surgical wounds. Most patients can be discharged the day following treatment based on medical advice.